Blood plasma biomarkers for combination therapies with bevacizumab for the treatment of pancreatic cancer

摘要

An in vitro method for identifying a patient who responds to or is sensitive to the addition of bevacizumab treatment to a chemotherapeutic regimen, said method comprising determining the level of protein expression of one or more of VEGFA, VEGFR2 and PLGF in a sample. of blood plasma from a patient suspected of having or prone to pancreatic cancer, whereby an increased expression level of one or more of VEGFA, VEGFR2 and PLGF relative to the control expression levels determined in patients Having pancreatic cancer is indicative of a patient's sensitivity to the addition of bevacizumab to such a chemotherapeutic regimen, where pancreatic cancer is metastatic pancreatic cancer and the chemotherapeutic regimen comprises gemcitabine and erlotinib.